• AbbVie entered a multi-year collaboration with Iambic to accelerate AI-driven discovery of small-molecule drugs across immunology, neuroscience, oncology.
• Partnership applies Iambic’s AI platform to improve hit identification efficiency, aiming to shorten development timelines for first-in-class or best-in-class candidates.
• Iambic will receive an upfront payment, success-based milestone payments, tiered royalties on net sales from products generated under the deal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG51829) on September 21, 2026, and is solely responsible for the information contained therein.